Nuvation Bio Inc.
10-K
March 2, 2026
Key Highlights
- Lead candidate NUV-400 advanced to Phase 2 in NSCLC after positive Phase 1 data,...
- NUV-650, an ADC, transitioned to clinical development with IND filing in Q3 2025...
- Strong cash position of $310.5 million at year-end 2025, projected to fund opera...
Read Analysis
π€ AI Generated